Lutein Iontophoresis in Intermediate AMD and Reticular Pseudodrusen - a Retrospective Study

N/ACompletedNCT07420361

Mario Damiano Toro30 enrolled

Overview

There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with in-termediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD). This retrospective multicentre study evaluated the functional and morphological outcomes of TSLI in patients with stage 2 and stage 3 iAMD with RPD. Autofluorescence (AF), Optical Coherence Tomography (OCT), Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), Macular Sensitivity (MS) and adverse events, were recorded at baseline, 1 month and 3 months follow-up after treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Intermediate Age-Related Macular Degeneration With Reticular Pseudodrusen

Eligibility

Sex: ALLMin age: 55 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion criteria * Age between 55 and 80 years old * diagnosis of early to intermediate stage dAMD (based on AREDS criteria) * presence of RPD * Treated with scleral Lutein Iontophoresis Exclusion Criteria: * GA or MNV in the included eye * any prior or any ongoing medical or surgical treatment of the included eye (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants) * smokers (consummation of more than 20 cigarettes per day) * history of treatment with drugs with a well-known possible ophthalmic side-effect * known eye diseases such glaucoma, acute or chronic uveitis, advanced cataract, stage 4 dry eye disease or any opacities of the ocular media that do not permit high-quality imaging examinations * manifest refraction outside of -6 and +4 dioptres * BCVA \< 40 EDTRS letters.